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Abstract
Purpose: To assess feasibility and safety of conventionally fractionated radiotherapy (cfRT) in patients with
hepatocellular carcinoma (HCC).
Methods: Patients with histologically confirmed stage cT1-4, cN0-1 HCC and Child-Pugh Score (CPS) A or B disease
were included in a phase I multicenter trial. Metastatic HCC were allowed if ≥90% of total tumor volume was located
within the liver. Patients were enrolled onto five dose-escalation levels (54–70Gy in 2Gy fractions) based on a modified
3 + 3 design, with cohorts of five patients instead of three patients in dose levels 4 and 5. Primary trial endpoint was
dose-limiting toxicity (DLT), as specifically defined for 17 clinical and nine laboratory parameters as grade ≥3 or ≥4
toxicity (CTCAE vs. 3). The threshold to declare a dose level as maximum tolerated dose (MTD) was defined as a DLT
rate of ≤16.7% in dose levels 1–3, and ≤10% in dose levels 4–5. Best objective response of target liver lesions and
adverse events (AE’s) were assessed as secondary endpoints.
Results: The trial was terminated early in DL 3 due to low accrual. Nineteen patients were recruited. Fifteen patients
were evaluable for the primary and 18 for the secondary endpoints. Maximum tolerated dose was not reached. One
patient in dose level 1, and one patient in dose level 2 experienced DLT (lipase > 5xULN, and neutrophils <500/μL
respectively). However, dose level 3 (62Gy) was completed, with no DLTs in 3 patients.
Overall, 56% of patients had a partial response and 28% showed stable disease according to RECIST. No signs of
radiation induced liver disease (RILD). Two patients in dose level 3 experienced lymphocytopenia grade 4, with no
clinical impact.
Conclusion: Conventionally fractionated radiotherapy of 58Gy to even large HCC was safe for patients with CPS A and
B. 62Gy was delivered to three patients without any sign of clinically relevant increased toxicity. The maximum tolerated
dose could not be determined.
Trial registration: ClinicalTrials.gov identifier NCT00777894, registered October 21st, 2008.
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Background
Hepatocellular carcinoma is the most common primary
liver tumor and the 2nd leading cause of cancer related
mortality worldwide. It represents 7% of all diagnosed
cancers and its overall 5-year survival rate < 12%. In
Europe, liver cirrhosis patients progress to HCC at a
conversion rate of approximately 3% per year in Europe
[1]. Prior to intensity-modulated radiotherapy (IMRT) or
stereotactic body radiotherapy (SBRT), use of external
beam radiotherapy (RT) has been quite limited in the
treatment of HCC [2]. The whole liver has a low toler-
ance to radiation and patients are at risk for unaccept-
able liver toxicity [3]. Radiation injury to the liver after
conventionally fractionated radiotherapy (cfRT), was first
described by Ingold et al. several decades ago [4]. The
clinical scenario of radiation induced liver disease RILD
consists of anicteric hepatomegaly, ascites, and elevated
alkaline phosphatase [5]. In the landmark report by
Emami et al. [3], the whole-liver tolerance dose (TD)
expected to yield a 5% risk of liver failure 5 years after
treatment (TD 5/5) for whole-liver radiation was
estimated to be 30Gy in 2Gy fractions. The Lyman
normal tissue complication probability (NTCP) model
and a local damage-organ injury NTCP model later have
been used to describe the partial tolerance of the liver to
RT [6]. Image-guided volumetric arc therapy (VMAT),
IMRT and SBRT dose delivery, allow reducing the dose
to non-tumor liver tissue, kidneys and the intestines.
Thus, dose escalation to the diseased liver segments has
become possible. This trial was conducted to obtain bet-
ter understanding of the RT dose-response-relationship
for tumor control as well as for normal tissue toxicities
in this patient group. We report the results of the Swiss
Group for Clinical Cancer Research (SAKK) 77/07 phase
I trial assessing feasibility and safety of cfRT in patients
with locally advanced non-resectable HCC.
Patients and Methods
Patients
Patients with unresectable, histologically or radiologic-
ally confirmed stage cT1–4, cN0–1 HCC, Barcelona
clinic liver cancer (BCLC) stage B and C with no prior
malignancy within 5 years were eligible for this phase I
trial. Patients had to be older than 18 years, with a Child-
Pugh A or B score, with a residual liver volume (= total
liver volume – the gross tumor volume (GTV)) of >800 ml
and ≥40% of uninvolved liver and WHO performance
status 0–2. Metastatic HCC was allowed if ≥90% of total
tumor volume was located within the liver. Exclusion
criteria included, ALT and AST ≥5x upper limit of normal
(ULN), AP ≥ 5 x ULN, bilirubin ≥3 x ULN, hemoglobin ≤
100 g/L, neutrophils ≤1.2 x 109/L, platelets ≤ 50 x 109/L,
international normalized ratio (INR) >2, creatinine clear-
ance ≤ 50 mL/min, clinical ascites, encephalopathy, active
hepatitis, gastric, duodenal, or variceal bleeding or weight
loss ≥ 15% within three months of registration or esopha-
geal varices ≥ grade 3 [7, 8]. Patients were also excluded, if
they had prior RT to the abdomen or caudal chest below
T5, prior transarterial chemoembolization (TACE) and
radiofrequency ablation (RFA) within eight weeks. No
chemotherapy was permitted within three weeks before
registration. Portal vein thrombosis (PVTT) was not an
exclusion criterion.
The study was planned and conducted in accordance
with the principles of the Declaration of Helsinki. The
protocol was approved by the ethics committee of each par-
ticipating site (ClinicalTrials.gov identifier NCT00777894,
registered October 21st, 2008). Written informed consent
was obtained from all patients.
Radiation therapy
Pretreatment triphasic diagnostic computed tomography
(CT) was used to delineate the gross tumor volume
(GTV) and enhanced area of vessel thrombosis. Patients
were treated in supine position. Respiratory gating or
breath holding techniques were used. Triphasic CT
simulation with intravenous contrast was used with a 3-
to 5-mm-slice thickness. The range of the simulation
CT scan included the whole liver, lower part of the
lungs, and both kidneys. The GTV was defined as the
visible tumor on the arterial phase of simulation CT
and/or fused diagnostic CT. For patients with coexisting
PVTT, the area of PVTT was included as a part of the
GTV. The clinical target volume (CTV) encompassed
the area of the GTV with a 5–10 mm margin. The CTV
was expanded by a 5- to 10-mm radial margin and a 6-
to 15-mm cranio-caudal margin to create the planning
target volume (PTV). Normal liver was defined as the
whole liver volume minus the PTV. Patients were
treated with either 3D-conformal RT (3D-CRT), IMRT
or fractionated stereotactic RT techniques, using 6–18
MV photon energies. Due to compatibility between
centers, dose prescription and normalization were fixed
at isocenter and for conformal therapy, according to the
international commission on radiation units and
measurements (ICRU) reports 50 and 62. In case of
IMRT, dose prescription and normalization could be
defined as mean dose to PTV for optimization reasons,
but for reporting it was rescaled to the isocenter. No
normalization/prescription to isodose levels was allowed.
For 3D-conformal planning: 2 to 5 portal beams with
planar or non-coplanar arrangement were used. Larger
number of fields was allowed to use to improve the qual-
ity of dose distribution [9]. For adequate target coverage,
the PTV received 95–107% of the prescribed total dose.
Alternatively, a minimum of 95% of the prescribed dose
had to encompass more than 99% of the PTV. In
addition, it was recommended that areas receiving more
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than 105% of the prescribed dose, are kept to <1% of the
PTV. Our protocol suggested that participants have >800
mL and > 40% of non-tumor liver and that the mean dose
has to be kept < 28Gy in patients with a non-cirrhotic
liver and < 24Gy in patients with signs of cirrhotic liver. If
the PTV encompassed >66% of the total liver volume,
radiotherapy was not initiated. RT was delivered from
Monday to Friday in five fractions per week, of 2Gy per
fraction to a total dose of 10Gy per week. Normal tissue
dose delivery guidelines for bowel, stomach, esophagus
(each Dmean < 40Gy, V60Gy <3%), lung (V5Gy <85%,
V20Gy <20% and Dmean < 12–15Gy), heart (Dmean
< 40Gy), spine (D1% <48Gy) and kidneys (Dmean left
kidney <12Gy and if V50% of right kidney irradiated
>20Gy, Dmean left kidney <5Gy) were provided to
facilitate planning [10, 11].
Escalation strategy
Patients were to be enrolled onto five dose-escalation
levels (54, 58, 62, 66 and 70Gy in 2Gy fractions, corre-
sponding to a biological effective dose (BED) of 162,
174, 186, 198 and 210Gy with an alpha/beta ratio of 10,
based on a modified 3 + 3 design. In dose levels 1 to 3,
three patients, and in dose level 4 and 5, five patients
had to be treated per cohort. Escalation to the next dose
level was only permitted once no DLT was established
within one month after the end of RT. If toxicity
occurred in dose levels 1–3, a minimum of six patients
and for dose level 4 and 5, a minimum of ten patients
needed to be treated at that level, before escalating to
the next level. While waiting until one month after RT,
at which time the presence or absence of toxicity was
determined, subsequent patients could be treated at the
pre-defined dose level, up to a dose of 44Gy. DLT was
specifically defined for 17 clinical and nine laboratory
parameters as grade ≥3 or ≥4 toxicity according to
CTCAE vs. 3. The threshold to declare a dose level as
MTD, was defined, as a DLT rate of ≤16.7% in dose
levels 1–3, and ≤10% in dose levels 4–5. A dose of 54Gy
was chosen as the lowest dose level, because doses up to
54Gy showed response rates at around 50% [12].
Quality assurance (QA)
Before starting patient accrual, each participating center
was required to successfully participate in a radiotherapy
specific quality assurance (RT-QA) program correspond-
ing to EORTC QART [13] levels 1 and 2: 1.) Facility
questionnaire External dosimetry audit (EDA), 2.)
dummy run (DR). For the DR an anonymized case
including CT data set was made available. Target
volumes (GTV, CTV, PTV) and all organs at risk (OAR)
were delineated by the center’s investigator and reviewed
by the coordinating investigator. Deviations from the
protocol were communicated to the participating center,
and a revised version of the delineated structures was re-
quested and reviewed. The approved structures were
then used to elaborate a treatment plan using the RT
technique chosen by the center. The plans were
reviewed by the trial chair and trial medical physicist,
which requested a revised version, in case of deviations
from the protocol.
An internal report comparing the anonymized DR re-
sults of the first five participating centers was made
available to those centers. Coincidence histograms [14]
were used for a quantitative topological comparison of
the delineated structures.
Evaluation
Patients were assessed weekly during RT, and after
completion of treatment, followed up for one year at 1,
2, 3, 5, 8 and 11 months. At the first month follow-up
physical examination, hemoglobin, neutrophils, platelets,
hepatic function, renal function, pancreatic lipase, INR
and CPS were reviewed. The reason for including
pancreatic lipase in the follow up examination was to
discover pancreatitis. Liver triphasic CT was performed
at 2 and 5 months after RT, thereafter every 3 months
until progression. At each follow-up within the first
three months after RT, toxicity was graded using the
CTCAE vs. 3. RILD was defined as the development of
nonmalignant ascites without disease progression and an
anicteric elevation of alkaline phosphatase level by at
least twofold. Non – classic RILD was defined as the
development of jaundice and/or elevated serum trans-
aminases (>5 x UL) within 3 months of completion of
RT in patients with underlying chronic hepatic disease
(cirrhosis or viral hepatitis). Best objective response of
target liver lesions was assessed using RECIST.
Statistics
Using a modified 3 + 3 design, the planned sample size
laid between two and 38 evaluable patients in case of
two DLTs in the first two patients and two full cohorts
at each dose level, respectively. For the primary end-
point, the following patients were considered evaluable:
either patients who experienced a DLT and received a
dose of at least 12Gy or patients who completed the
treatment according to their dose level. Non-evaluable
patients were to be replaced. Primary endpoint was
DLT. Best objective response of target liver lesions and
adverse events were assessed as secondary endpoints.
Local control was defined as time from registration to
progression of target lesions or death due to progression,
whichever occurred first. Overall survival was the time
from registration to death from any cause. The rates at
one year of these survival times were estimated using
the Kaplan-Meier estimator. Point estimates and, if
applicable, the corresponding exact 95% confidence
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interval were calculated for proportions. Median follow-
up time was calculated using the reverse Kaplan-Meier
method. All data were collected and analyzed at the
SAKK coordinating center in Bern, Switzerland.
Analyses were performed using SAS 9.2.
Results
The trial was terminated early due to low accrual.
Therefore only dose levels 1–3 (54, 58 and 62Gy) were
examined.
Patients
From November 2008 to January 2014, 19 patients from
five centers within Switzerland and the Netherlands
were recruited; six patients at dose level 1, seven patients
at dose level 2 and six patients at dose level 3. One
patient was not treated at all with RT because of inad-
equate normal liver volume < 800 ml and therefor not
evaluable for both endpoints.
In DL 3, three additional patients were not evaluable
for the primary endpoint: two died during treatment one
due to cardiac failure and one due to pneumonia (at 26
and 30Gy in 2Gy per fraction, respectively), and one
because laboratory values were repeatedly not measured,
making it impossible to assess DLT. The remaining 15
patients completed RT as planned, and were evaluable
for the primary endpoint. For the secondary endpoints,
18 patients (95%) were evaluable. Median follow up time
was 11.8 months. The median age was 68 years (range
45–82 years, inter-quartile range 62–77). The majority
of HCC patients had stage cT3 (47%), cN0 (84%) disease,
CP-score A5 (58%) and WHO performance status 0
(53%). Alcohol was the most common etiology of the
underlying liver cirrhosis (74%). Two patients (11%) had
M1 disease. Median longest diameter of largest lesion
was 68 mm (range 18–230 mm). Median administered
RT dose was 57Gy (range 26–62Gy in 2Gy per frac-
tion). Other baseline patient characteristics can be
found in Table 1. Median longest diameter of largest
lesion was 70 mm (range 18–185 mm). Median
administered RT dose was 57Gy (range 26–62Gy in
2Gy per fraction).
Toxicity
At dose levels 1 and 2, six patients each and at dose
levels 3, three patients were evaluable. One (17%) of 6
patients in dose level 1 and one (17%) of six patients in
dose level 2 experienced DLTs (lipase > 5xULN and
neutrophils <500/μL). Both, dose levels 1 and 2 had a
DLT each among the first three patients, requiring an
additional three patients at the same dose level as per
protocol. However, dose level 3 (62Gy) was completed,
with no DLTs in three patients. Two patients died during
RT treatment, one patient in dose level 2 due to cardiac
Table 1 Patient characteristics of all registered patients (n = 19)
Variable Value
(N = 19)
Age [years]
Median (Min–Max), N = 19 68 (45–82)
Gender
F 3 (16%)
M 16 (84%)
T stage
1 2 (11%)
2 4 (21%)
3 9 (47%)
4 4 (21%)
N stage
0 16 (84%)
1 3 (16%)
M stage
0 17 (89%)
1 2 (11%)
Total Child-Pugh score
5 11 (58%)
6 4 (21%)
7 3 (16%)
8 1 (5%)
WHO performance status
0 10 (53%)
1 7 (37%)
2 2 (11%)
BCLC classification
0 1 (5%)
A 1 (5%)
B 10 (53%)
C 7 (37%)
Vascular invasion
Yes 8 (44%)
No 9 (50%)
Unknown 1 (6%)
Missing 1
Previous therapies (more than 1 possible)
TACE 2 (11%)
TAE 1 (5%)
PEI 0
Local thermal ablation 1 (5%)
Liver resection 2 (11%)
Systemic treatment 3 (16%)
Other 0
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failure, and one in dose level 3 due to pneumonia. One
patient in dose level 3 died during follow-up, due to
cardiac failure. None of the deaths were related to RT
treatment. None of the in total evaluated patients showed
any signs of RILD. At dose level 1, one patient developed
an elevated lipase value grade 4 (Lipase > 5 x ULN) during
the first week of RT, which subsequently normalized on
laboratory follow-up. A second patient showed an elevated
grade 4 bilirubin value (Total bilirubin > 10 x ULN) one
month after RT, which normalized, and a third patient
showed an isolated elevated AST grade 4 (AST > 20 x
ULN) three months after RT, which also normalized dur-
ing the subsequent analyses. At dose level 2, one patient
experienced neutropenia grade 4 (neutrophils <500/μL) in
week 6 of RT and at dose level 3, two patients each experi-
enced lymphocytopenia grade 4 (lymphocytes < 200/mm3)
during week 5 and 6 as well as during week 6 and at the
end of RT, with no clinical impact.
Response rate
The overall RECIST response rate was 56% (95% CI
31–78%), with 0% complete response (CR), 56% par-
tial response (PR) and 28% stable disease (SD). In
three patients (16%), treated at dose level 3, no re-
sponse (NR) could be determined. Two patients died
and one had symptomatic deterioration before their
first CT scan after baseline. An overview of response
rate according to DL and CP-Score are shown in
Tables 2 and 3. The most frequent site of first
progression was outside the treated volume. One-
year survival and 1-year local control in this small
cohort is 61% (95% CI: 35–79%) and 89% (95% CI
43–98%), respectively, which were not endpoints
within the trial (Fig. 1).
Discussion
We present the data of an international multicenter
phase I study of 18 patients treated with cfRT for locally
advanced non-resectable HCC. In contrast to previously
published prospective studies [10, 15–18], DLT in the
present trial was specifically defined for 17 clinical and
nine laboratory parameters as grade ≥3 or ≥4 toxicity
(CTCAE vs. 3), to address the safety aspect from a
biochemical point of view. Additionally, our study-
population had large tumors (median 86 mm, range 18–
230 mm) and 20% of patients had a CP B score. Even in
such a vulnerable patient collective, the present trial
showed that cfRT of 58Gy to HCC is safe in an inter-
national multicenter setting. A total dose of 62Gy was
delivered to three patients without any sign of clinical
relevant increased toxicity. However, the maximum tol-
erated dose could not be determined due to the early
termination of the trial because of patient accrual. The
reasons for very slow patient accrual included several
competing focal treatment options (e.g. RFA, TACE) in
liver tumors and the rapid evolvement of SBRT. RT was
well tolerated in this study, and no signs of RILD were
observed. The DLTs at dose level 1 (54Gy) and 2 (58Gy)
(lipase > 5xULN and neutrophils <500/μL) were not
clinically relevant. The increased lipase value occurred
in the first week of RT at DL 1 and was most likely not
related to RT, since it normalized in the subsequent
weeks of treatments, when higher cumulative doses were
applied. The decreased granulocyte value may have cor-
responded to an increased granulocyte consumption,
which may be interpreted as an expression of intermit-
tent hepatocyte injury [19]. During follow-up, there was
a spontaneous remission of the neutrophils in the
physiological range. Therefore it is questionable to use
the lipase and neutrophils as a dose-limiting factor for
Table 1 Patient characteristics of all registered patients (n = 19)
(Continued)
Longest diameter of largest lesion [mm]
Median (Min–Max), N = 19 86 (18–230)
Gross tumor volume [ml]
Median (Min–Max), N = 19 340 (10–3582)
Total liver volume [ml]
Median (Min–Max), N = 19 2136 (948–3400)
Residual liver volume [ml]
Median (Min–Max), N = 19 1630 (906–2283)
Etiology of underlying liver disease (more than 1 possible)
Hepatitis B 1 (5%)
Hepatitis C 2 (11%)
Alcohol 14 (74%)
Unknown 3 (16%)
Table 2 Overall response of target lesions according to RECIST
v1.0 by DL
Overall DL 1
(54Gy)
DL 2
(58Gy)
DL 3
(62Gy)
Best response (N) 18 6 6 6
PR 10 (56%) 4 (67%) 4 (67%) 2 (33%)
SD 5 (28%) 2 (33%) 2 (33%) 1 (17%)
NA 3 (17%) 3 (50%)
Table 3 Overall response of target lesions according to RECIST
v1.0 by CPS
CPS A CPS B
Best response (N) 14 4
PR 8 (57%) 2 (50%)
SD 4 (29%) 1 (25%)
NA 2 (14%) 1 (25%)
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RT induced liver injury. The isolated bilirubin elevation
one month after RT and isolated AST elevation at 3
months after RT were only present at dose level 1. No
patient in dose level 2 and 3 had similar laboratory
changes, even though higher doses were applied. The
grade 4 adverse events were transient, and all patients
recovered spontaneously within a few months. None of
the two patient’s deaths in this trial were related to RT
treatment.
Several studies showed that it is safe to treat HCC
patients with cfRT in HCC. In a series of prospective tri-
als [10, 15–18], the University of Michigan group first
established the safety of an individualized dose allocation
approach for liver cancer. They developed a NTCP
model that quantitatively described the relationship
between dose and volumes irradiated and the probability
of developing classic RILD using conformal RT tech-
niques. Radiation dose was individualized based on the
volume of normal liver that could be spared without
exceeding a 5–20% risk of RILD. Objectively measurable
disease was not an entry criterion, although it was
followed when available. The prescribed doses ranged
from 40–90Gy (median, 60.75Gy) in 1.5Gy twice-daily
fractions delivered with concurrent hepatic arterial fluor-
odeoxyuridine [2]. In a phase II trial, Ben-Josef et al. [10]
reported median survival of 15.8 months with a trend to
improved survival (23.9 vs. 14.9 months) in patients
treated with doses of ≥75Gy. Doses below 60Gy had
little effect on survival and then a steady increase in
survival was observed as RT dose increased to 90Gy. Of
the 128 patients, 30% patient developed mostly
biochemical grade 3 to 4 toxicity, five patients (4%) de-
veloped RILD. In a large retrospective series from Korea
[20] including 158 HCC patients with CPS A or B were
treated with 25–60Gy in 1.8Gy daily fractions. The
patient selection was similar to the one of the present
trial. Median overall survival time was 10 months, with
no grade 4 or 5 toxicity reported. They demonstrated
that the CP score was a significant factor in the develop-
ment of RILD and the total radiation dose was the only
significant factor determining the tumor response. The
same group [21] reported in a retrospective patterns of care
study of 398 patients, with HCC treated at 10 institutions
in Korea, that CPS A, tumor size <5 cm, negative lymph
nodes and BED > 53.1Gy (alpha/beta of 10) were significant
factors for a better prognosis. In their collective BEDs
between 4.2–124.3Gy were delivered, the median survival
time was 12 months, and the 2-year overall survival rate
was 27.9%.
For that reason we suggest, that dose escalation,
exceeding 62Gy, should be chosen based on the NTCP
of the surrounding liver tissue. One-year survival and 1-
year local control in our trial with this vulnerable cohort
were 61% and 89%, respectively, although they were not
endpoints in the present study.
The overall RECIST response rate in our trial was
56%, with no patient showing a CR. Mornex et al. [22]
showed in their phase II trial, including 27 patients, a
92% response rate using the WHO and RECIST 1.0
criteria. Ninety-six percent of patients received an RT
dose of 66Gy. However, they only included patients with
small-size HCC between ≥30 and ≤50 mm, whereas in
our trial, tumor size ranged from 18–230 mm. Of all
patients, 41% developed grade ≥3 toxicity: 19% asymp-
tomatic grade 3 laboratory parameters toxicities in CPS
A patients and 27% grade 4 laboratory parameters toxic-
ities, 15% late grade 3 toxicity consisting of gastric
bleeding requiring transfusion, and edematous-ascitic
hepatic decompensation requiring paracentesis and
diuretics in CPS B patients.
Liu et al. [23] treated 44 patients with large HCC
(60–250 mm) with 40–60Gy in standard fractionation.
Tumor response was based on serial CT scans, with an
overall response rate of 61% using the WHO response
rating criteria. Radiation-induced toxicities remained
mild and reversible. Their results are comparable with
the results of our study. Similarly, a retrospective study
of Toya et al. [24] treated 38 HCC patients with PVTT
and tumor sizes ranging from 9 to 93 mm. A total dose
of 17.5–50.4Gy (median 40Gy), in 1.8–4Gy per fraction
was delivered, which translated to a BED of 23.4–59.5Gy
(median 50.7Gy) with an alpha/beta of 10. Response rate
was 44.7%. In 13 patients treated with 45Gy in 3Gy per
fraction, the response rate was 76.9%. The PVTT size
(≤30 mm vs. ≥ 30 mm) and BED ≥58Gy (alpha/beta of
10) were factors, which significantly were influencing
response rate and survival. The median- and one-year
survival was 9.6 months and 39.4%, respectively.
However, using the RECIST criteria to evaluate RT
response rate is outdated. It has been shown that exten-
sive tumor necrosis after loco-regional ablative treat-
ment or systemic chemotherapy may not always be
followed by an overall reduction in tumor diameter. In
some instances the lesion size may even increase due to
necrosis [25]. Several recent studies [26–30] have dem-
onstrated that quantification of residual viable tumor by
Fig. 1 Kaplan-Meier curves for local control and overall survival
Herrmann et al. Radiation Oncology  (2017) 12:12 Page 6 of 9
the European Association for Study of the Liver (EASL)
and modified RECIST (mRECIST) guidelines better pre-
dict treatment response compared with WHO and
RECIST guidelines. Volumetric response assessment is
likely to become the gold standard for defining treat-
ment response [31, 32]. Our protocol was written during
a period of time, when the mRECIST guidelines were
not standard yet. The available literature on response
rates after cfRT reports in WHO or RECIST criteria.
The presented data is well comparable with the
existing data within the literature. However, it has its
limitations. It is a small number of patients and the
maximum tolerated dose could not be determined due
to the early termination of the trial. Also the trial
duration was long. During this time period other effect-
ive treatment techniques such as SBRT or proton beam
therapy have evolved. SBRT refers to the use of stereo-
tactic non-coplanar conformal radiation therapy to
precisely deliver a large ablative radiation dose in a small
number of fractions, while limiting the dose to adjacent
normal tissues. The steep dose gradient within the target
volume leads to tight conformity with steep and
isotropic dose fall-off and high dose delivery to the
target volume [33]. There is a growing SBRT experience,
mostly in patients with small (<6 cm) HCC [34–38] with
a high local control ranging from 70–90% at one and
two years. In a large Canadian phase I/II study by Bujold
et al. [39], 102 patients with locally advanced HCC
(median size, 10 cm) were treated with six fractions of
SBRT, with a 1-year local control rate of 87% and
median OS of 17 months. Despite limiting their study to
a CP A score population, CP class deterioration occurred
in 29% at 3 months. Proton radiotherapy has also
emerged as a treatment option for patients with local-
ized HCC. It enables further dose escalation and precise
dose delivery while maintaining a favorable toxicity
profile. Various phase II trials have demonstrated the
effectiveness and toxicity profile of this therapy [40–42].
Recent studies have compared SBRT and proton beam
therapy to other focal treatment options such as RF or
TACE [43–45] in early stage HCC patients. Wahl et al.
[43] have published a retrospective study comparing SBRT
to RF in inoperable patients with small HCC. For tumors
treated with RFA, freedom from local progression (FFLP)
at two years was 80.2% vs. 83.8% for SBRT. Increasing
tumor size was predictive for FFLP in patients treated with
RFA (hazard ratio [HR], 1.54 per cm; p = 0.006), but not
for those treated with SBRT (HR, 1.21 per cm; p = 0.617).
For tumors ≥2 cm, there was decreased FFLP for RFA
compared with SBRT (HR, 3.35; p = 0.025). Takeda et al.
[44] conducted a phase II study, treating 90 CP A and B
score patients with a solitary HCC lesion up to a diameter
of 4 cm, unsuitable for resection and RF with SBRT and
optional TACE. Three-year LC rate and OS was 96.3%
and 66.7% (95% CI, 56.3–75.6%) respectively. In an other
phase II study Bush et al. [45] compared proton beam
therapy to TACE as a bridge for transplantation. In an
interim analysis of 69 subjects, ten TACE and 12 proton
patients underwent liver transplantation after treatment.
Viable tumor identified in the explanted livers after
TACE/proton averaged 2.4 and 0.9 cm, respectively.
Pathologic complete response after TACE/proton was
10%/25% (p = 0.38). The two-year OS for all patients was
59%, with no difference between treatment groups.
Median survival time was 30 months (95% CI 20.7–39.3
months). There was a trend toward improved two-year
LC (88% vs. 45%, p = 0.06) and progression-free survival
(48% vs. 31%, p = 0.06) favoring the proton beam treat-
ment group.
However, large, inoperable HCC > 10 cm, remain
challenging for treatment, because of close proximity to
critical organ, limited liver volume available and a rela-
tively poor liver functional status. In this small niche of
treatment indications, when locally ablative treatments
like RFA, TACE or SBRT are not possible, cfRT remains
a valid treatment approach for liver cancer [46]. Conven-
tional fractionation schedules may be more robust for
certain patients with large tumors or at risk for fibrosis
of the biliary ducts. The relatively high alpha/beta ration
of 8 [47] of liver tissue implies highly conformal therapy,
if treatment is completed within a few sessions. Never-
theless, the use of SBRT is being preferred whenever
feasible. The steep dose gradient within the target
volume leads to tight conformity with steep and
isotropic dose fall-off and high dose delivery to the tar-
get volume and requires, due to the complementary
information, when ever available the addition of MRI
imaging to GTV delineation as well as appropriate
motion control [48].
Despite increasing utilization, and prospective phase II
studies [39] describing favorable outcomes, SBRT for
liver cancer is still not included in practice guidelines
[49–51]. There is currently one randomized phase III
trial by the RTOG (RTOG 1112, (ClinicalTrials.gov ID:
NCT01730937) open for accrual, comparing Sorafenib
versus SBRT followed by Sorafenib in locally advanced
HCC. This trial hopefully will help to better clarify the
role of RT in HCC.
Conclusion
This multicenter trial showed that conventionally frac-
tionated radiotherapy delivering 58Gy to large primary
tumors of the liver was safe for patients with CPS A and
B. The dose of 62Gy was delivered to three patients
without any sign of increased toxicity. However, the
maximum tolerated dose could not be determined due
to the early termination of the trial. Randomized trials
are warranted to further define the role of cfRT and
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SBRT within multimodal treatment concepts for unre-
sectable HCC.
Abbreviations
3D-CRT: 3D-conformal RT; BED: Biologically effective dose;
cfRT: Conventionally fractionated radiotherapy; CPS: Child-Pugh score;
CR: Complete response; CT: Computed tomography; CTCAE vs. 3: Common
toxicity criteria for adverse events version 3.0; CTV: Clinical target volume;
DLT: Dose-limiting toxicity; DR: Dummy run; EASL: European Association for
Study of the Liver; EDA: External dosimetry audit; GTV: Gross tumor volume;
HCC: Hepatocellular carcinoma; IMRT: Intensity-modulated radiotherapie;
INR: International normalized ratio; mRECIST: Modified RECIST; MTD: Maximum
tolerated dose; NR: No response; NTCP: Normal tissue complication probability;
OAR: Organs at risk; PR: Partial response; PTV: Planning target volume;
PVTT: Portal vein thrombosis; RECIST: Response evaluation criteria in solid
tumors; RFA: Radiofrequency ablation; RILD: Radiation induced liver disease;
RT: Radiotherapy; RT-QA: Radiotherapy specific quality assurance; SAKK: Swiss
Group for Clinical Cancer Research; SBRT: Stereotactitc body radiotherapy;
SD: Stable disease; TACE: Transarterial chemoembolization; TD: Tolerance dose;
ULN: Upper limit of normal; VMAT: Volumetric arc therapy
Acknowledgements
Not applicable.
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article.
Authors’ contributions
Each author had participated sufficiently in the work to take public
responsibility for appropriate portions of the content. IFC, DN, JFD and DMA
designed this Study. MB performed the statistical analysis. All authors helped
to interpret the data. The manuscript was written by EH, MS and MB, all
other authors helped and finally approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was planned and conducted in accordance with the principles of the
Declaration of Helsinki. The protocol was approved by the ethics committee of
each participating site (ClinicalTrials.gov identifier NCT00777894, registered
October 21st, 2008). Written informed consent was obtained from all patients.
Financial support
By the Carolito Fundation, Swiss Foundation for Clinical Cancer Research and
the Swiss Federal Secretariat for Education, Research and Innovation.
Author details
1Department of Radiation Oncology, Inselspital, Bern University Hospital and
University of Bern, Bern, Switzerland. 2Division of Radiation Oncology, Basel
University Hospital, Basel, Switzerland. 3Department of Radiation Oncology,
Lifehouse at RPA, Sydney, NSW, Australia. 4Department of Radiation
Oncology and Division of Medical Radiation Physics, Bern University Hospital,
Bern, Switzerland. 5SAKK Coordinating Center, Bern, Switzerland. 6Department
of Radiation Oncology (MAASTRO Clinic), GROW – School for Oncology and
Developmental Biolog, Maastricht, The Netherlands. 7Department of
Radiation Oncology, University of Zurich, Zurich, Switzerland. 8Department of
Radiotherapy and Radiation Oncology, Dessau City Hospital, Dessau,
Germany. 9Department of Radiation Oncology, Hospital Graubuenden, Chur,
Switzerland. 10Radiation Oncology Department, Oncology Institute of
Southern Switzerland, Bellinzona, Switzerland. 11Radiotherapy Service, Clinica
Luganese SA, Lugano, Switzerland. 12Centre for Radiation Oncology, KSA-KSB,
Kantonsspital Aarau, Aarau, Switzerland. 13Department of Hepatology,
University Clinic of Visceral Surgery and Medicine, Inselspital, Bern University
Hospital and University of Bern, Bern, Switzerland.
Received: 7 July 2016 Accepted: 21 December 2016
References
1. Mittal S. El-Serag HB Epidemiology of hepatocellular carcinoma: consider
the population. J Clin Gastroenterol. 2013;47(Suppl):S2–6. doi:10.1097/MCG.
0b013e3182872f29.
2. Feng M, Ben-Josef E. Radiation therapy for hepatocellular carcinoma. Semin
Radiat Oncol. 2011;21(4):271–7. doi:10.1016/j.semradonc.2011.05.002.
3. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B,
Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int
J Radiat Oncol Biol Phys. 1991;21(1):109–22.
4. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation Hepatits. Am
J Roentgenol Radium Ther Nucl Med. 1965;93:200–8.
5. Guha C. Kavanagh BD Hepatic radiation toxicity: avoidance and
amelioration. Semin Radiat Oncol. 2011;21(4):256–63.
6. Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation.
Semin Radiat Oncol. 2005;15(4):279–83.
7. National Cancer Institute CTEP. CTCAE v3.0. Available at: https://ctep.cancer.
gov/protocolDevelopment/electronic_applications/ctc.htm. Accesed 23 Dec
2016.
8. Cheng JC, Wu JK, Huang CM, Liu HS, Huang DY, Cheng SH, et al. Radiation-
induced liver disease after three-dimensional conformal radiotherapy for
patients with hepatocellular carcinoma: dosimetric analysis and implication.
Int J Radiat Oncol Biol Phys. 2002;54:156–62.
9. Ciernik IF, Lawrence TS. Radiation Therapy for Liver Tumors. In Clavien
(second edition), Malignant Liver Tumors: Current and Emerging Therapies.
Sudbury: Lones et Bartlett Publishers, Inc.; 2004. p. 101–9.
10. Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK,
Knol J, Dawson LA, Pan C, Lawrence TS. Phase II trial of high-dose
conformal radiation therapy with concurrent hepatic artery floxuridine for
unresectable intrahepatic malignancies. J Clin Oncol. 2005;23(34):8739–47.
11. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A,
Bentzen SM, Nam J, Deasy JO. Use of normal tissue complication probability
models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9.
12. Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK,
Kim CM. Three-dimensional conformal radiotherapy of unresectable
hepatocellular carcinoma patients for whom transcatheter arterial
chemoembolization was ineffective or unsuitable. Am J Clin Oncol.
2006;29(6):568–75.
13. Weber DC, Poortmans PM, Hurkmans CW, Aird E, Gulyban A. Fairchild A
Quality assurance for prospective EORTC radiation oncology trials: the
challenges of advanced technology in a multicenter international setting.
Radiother Oncol. 2011;100(1):150–6. doi:10.1016/j.radonc.2011.05.073. Epub
2011 Jun 29.
14. Schiefer H, von Toggenburg F, Seelentag WW, Plasswilm L, Ries G, Schmid
HP, Leippold T, Krusche B, Roth J, Engeler D. Topological methods for the
comparison of structures using LDR-brachytherapy of the prostate as an
example. Phys Med Biol. 2009;54(16):4959–70. doi:10.1088/0031-9155/54/16/
008. Epub 2009 Jul 30.
15. Robertson JM, McGinn CJ, Walker S, Marx MV, Kessler ML, Ensminger
WD, Lawrence TS. A phase I trial of hepatic arterial bromodeoxyuridine
and conformal radiation therapy for patients with primary hepatobiliary
cancers or colorectal liver metastases. Int J Radiat Oncol Biol Phys.
1997;39(5):1087–92.
16. McGinn CJ, Ten Haken RK, Ensminger WD, Walker S, Wang S, Lawrence TS.
Treatment of intrahepatic cancers with radiation doses based on a normal
tissue complication probability model. J Clin Oncol. 1998;16(6):2246–52.
17. Dawson LA, McGinn CJ, Normolle D, Ten Haken RK, Walker S, Ensminger W,
Lawrence TS. Escalated focal liver radiation and concurrent hepatic artery
fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol.
2000;18(11):2210–8.
18. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK.
Analysis of radiation-induced liver disease using the Lyman NTCP model. Int
J Radiat Oncol Biol Phys. 2002;53(4):810–21.
19. Silbernagl S, Lang F. Taschenatlas Pathophysiologie. Thieme Verlag, 4.
aktualisierte und erweiterte Auflage; 2013. p. 186
20. Park HC, Seong J, Han KH, et al. Dose- response relationship in local
radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys.
2002;54:150–5.
Herrmann et al. Radiation Oncology  (2017) 12:12 Page 8 of 9
21. Seong J, Lee IJ, Shim SJ, Lim do H, Kim TH, Kim JH, Jang HS, Kim MS, Chie
EK, Kim JH, Nam TK, Lee HS, Han CJ. A multicenter retrospective cohort
study of practice patterns and clinical outcome on radiotherapy for
hepatocellular carcinoma in Korea. Liver Int. 2009;29(2):147–52.
22. Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C, Merle P. Feasibility
and efficacy of high-dose three-dimensional-conformal radiotherapy in
cirrhotic patients with small-size hepatocellular carcinoma non-eligible for
curative therapies–mature results of the French Phase II RTF-1 trial. Int J
Radiat Oncol Biol Phys. 2006;66(4):1152–8.
23. Liu MT, Li SH, Chu TC, Hsieh CY, Wang AY, Chang TH, Pi CP, Huang CC,
Lin JP. Three-dimensional conformal radiation therapy for unresectable
hepatocellular carcinoma patients who had failed with or were
unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol.
2004;34(9):532–9.
24. Toya R, Murakami R, Baba Y, Nishimura R, Morishita S, Ikeda O, Kawanaka K,
Beppu T, Sugiyama S, Sakamoto T, Yamashita Y, Oya N. Conformal radiation
therapy for portal vein tumor thrombosis of hepatocellular carcinoma.
Radiother Oncol. 2007;84(3):266–71.
25. Seyal AR, Gonzalez-Guindalini FD, Arslanoglu A, Harmath CB, Lewandowski
RJ, Salem R, Yaghmai V. Reproducibility of mRECIST in assessing response to
transarterial radioembolization therapy in hepatocellular carcinoma.
Hepatology. 2015;62(4):1111–21.
26. Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, Lee BJ, Seo YS, Yim HJ,
Seo TS, Lee CH, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. Comparison of the
methods for tumor response assessment in patients with hepatocellular
carcinoma undergoing transarterial chemoembolization. J Hepatol.
2013;58(6):1181–7. doi:10.1016/j.jhep.2013.01.039. Epub 2013 Feb 8.
27. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs
AK, Meyer T. EASL and mRECIST responses are independent prognostic
factors for survival in hepatocellular cancer patients treated with
transarterial embolization. J Hepatol. 2011;55(6):1309–16.
28. Li H, Guo Z, Si T, Wang H. EASL and mRECIST responses are independent
predictors of survival in hepatocellular carcinoma patients treated with
cryoablation. Eur J Gastroenterol Hepatol. 2013;25(5):620–7.
29. Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, Kim HS.
mRECIST and EASL responses at early time point by contrast-enhanced
dynamic MRI predict survival in patients with unresectable hepatocellular
carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial
chemoembolization (DEB TACE). Ann Oncol. 2013;24(4):965–73.
30. Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ. Which response
criteria best help predict survival of patients with hepatocellular carcinoma
following chemoembolization? A validation study of old and new models.
Radiology. 2012;262(2):708–18.
31. Rothe JH, Grieser C, Lehmkuhl L, Schnapauff D, Fernandez CP, Maurer MH,
Mussler A, Hamm B, Denecke T, Steffen IG. Size determination and response
assessment of liver metastases with computed tomography–comparison of
RECIST and volumetric algorithms. Eur J Radiol. 2013;82(11):1831–9.
32. Wulff AM, Fabel M, Freitag-Wolf S, Tepper M, Knabe HM, Schäfer JP,
Jansen O, Bolte H. Volumetric response classification in metastatic solid
tumors on MSCT: initial results in a whole-body setting. Eur J Radiol.
2013;82(10):e567–73.
33. Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for
hepatocellular carcinoma. World J Gastroenterol.
2014;20(12):3100–11.
34. Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen
BJ, Nowak PC, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN,
Levendag PC. Stereotactic body radiation therapy for primary and
metastatic liver tumors: A single institution phase i-ii study. Acta Oncol.
2006;45(7):831–7.
35. Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE,
Henderson MA, Schefter TE, Tudor K, Deluca J, Johnstone PA. Phase I
feasibility trial of stereotactic body radiation therapy for primary
hepatocellular carcinoma. Clin Transl Oncol. 2010;12(3):218–25.
doi:10.1007/s12094-010-0492-x.
36. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK,
Chung KW. Long-term effect of stereotactic body radiation therapy for
primary hepatocellular carcinoma ineligible for local ablation therapy or
surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer.
2010;10:475. doi:10.1186/1471-2407-10-475.
37. Seo YS, Kim MS, Yoo SY, Cho CK, Choi CW, Kim JH, Han CJ, Park SC, Lee BH,
Kim YH, Lee DH. Preliminary result of stereotactic body radiotherapy as a
local salvage treatment for inoperable hepatocellular carcinoma. J Surg
Oncol. 2010;102(3):209–14. doi:10.1002/jso.21593.
38. Louis C, Dewas S, Mirabel X, Lacornerie T, Adenis A, Bonodeau F, Lartigau E.
Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results.
Technol Cancer Res Treat. 2010;9(5):479–87.
39. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE,
Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA.
Sequential phase I and II trials of stereotactic body radiotherapy for locally
advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631–9.
40. Bush DA, Kayali Z, Grove R, et al. The safety and efficacy of high- dose
proton beam radiotherapy for hepatocellular carcinoma: A phase 2
prospective trial. Cancer. 2011;117:3053–9.
41. Kawashima M, Furuse J, Nishio T, et al. Phase II study of radiotherapy
employing proton beam for hepatocellular carcinoma. J Clin Oncol.
2005;23:1839–46.
42. Fukumitsu N, Sugahara S, Nakayama H, et al. A prospective study of
hypofractionated proton beam therapy for patients with hepatocellular
carcinoma. Int J Radiat Oncol Biol Phys. 2009;74:831–6.
43. Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper
MJ, Feng M. Outcomes After Stereotactic Body Radiotherapy or
Radiofrequency Ablation for Hepatocellular Carcinoma. J Clin Oncol.
2016;34(5):452–9.
44. Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, Imajo
K, Aoki Y, Saito H, Kunieda E. Phase 2 study of stereotactic body
radiotherapy and optional transarterial chemoembolization for solitary
hepatocellular carcinoma not amenable to resection and radiofrequency
ablation. Cancer. 2016;122(13):2041–9.
45. Bush DA, Smith JC, Slater JD, Volk ML, Reeves ME, Cheng J, Grove R, de Vera
ME. Randomized Clinical Trial Comparing Proton Beam Radiation Therapy
with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results
of an Interim Analysis. Int J Radiat Oncol Biol Phys. 2016;95(1):477–82.
46. Dawson LA. Overview: Where does radiation therapy fit in the spectrum of
liver cancer local-regional therapies? Semin Radiat Oncol. 2011;21(4):241–6.
doi:10.1016/j.semradonc.2011.05.009.
47. Son SH, Jang HS, Lee H, Choi BO, Kang YN, Jang JW, Yoon SK, Kay CS.
Determination of the α/β ratio for the normal liver on the basis of radiation-
induced hepatic toxicities in patients with hepatocellular carcinoma. Radiat
Oncol. 2013;8:61. doi:10.1186/1748-717X-8-61.
48. Hong TS, Bosch WR, Krishnan S, Kim TK, Mamon HJ, Shyn P, Ben-Josef E,
Seong J, Haddock MG, Cheng JC, Feng MU, Stephans KL, Roberge D, Crane
C, Dawson LA. Interobserver variability in target definition for hepatocellular
carcinoma with and without portal vein thrombus: radiation therapy
oncology group consensus guidelines. Int J Radiat Oncol Biol Phys.
2014;89(4):804–13.
49. Benson 3rd AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM,
Covey A, Curley SA, D’Angelica MI, Davila R, Ensminger WD, Gibbs JF,
Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA,
Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP,
Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology:
hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7(4):350–91.
50. European Association for Study of Liver. European Organisation for Research
and Treatment of Cancer. EASL-EORTC clinical practice guidelines:
Management of hepatocellula carcinoma. Collaborators: Llovet JM, Ducreux
M, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, Greten TF, Raymond E,
Roskams T, De Baere T, Ducreux M, Mazzaferro V, Bernardi M, Bruix J,
Colombo M, Zhu A. J Hepatol. 2012;56:908–943
51. Bruix J, Sherman M, American Association for the Study of Liver Diseases.
Management of hepatocellular carcinoma: an update. Hepatology.
2011;53(3):1020–2.
Herrmann et al. Radiation Oncology  (2017) 12:12 Page 9 of 9
